NCT06703567 IMproving PAtient UndeRstanding of GEP TEst Results: Phase 4
| NCT ID | NCT06703567 |
| Status | Recruiting |
| Phase | — |
| Sponsor | European Institute of Oncology |
| Condition | Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 82 participants |
| Start Date | 2024-09-06 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 82 participants in total. It began in 2024-09-06 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary aim of the study is to determine if provision of a patient information film about Oncotype DX improves patients' knowledge and understanding about Gene Expression Profiling (GEP) test and risk of recurrence results in early breast cancer (EBC) patients, identified by their clinical teams as potentially benefiting from having their tumor samples sent for GEP analysis.
Eligibility Criteria
Inclusion Criteria: * First presentation of early stage breast cancer with all known disease surgically removed * Estrogen Receptor (ER) positive and Human Epidermal growth factor Receptor 2 (HER-2) negative * No clear decision on whether chemotherapy should be given as adjunct based on current prognostic criteria * Consented to GEP testing * Able to give full informed consent to IMPARTER study * Good comprehension of the Italian language * Access to internet connection and devices (e.g. smart phone, tablet, laptop or desktop computer) Exclusion Criteria: * Other breast cancer diagnosis (e.g. Ductal carcinoma in situ, Metastatic) * Unable to give fully informed consent * Under 18 years of age * Unable to understand and speak Italian * No access to internet connection or devices
Contact & Investigator
Gabriella Pravettoni, MD
PRINCIPAL INVESTIGATOR
European Istitute of Oncology
Frequently Asked Questions
Who can join the NCT06703567 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06703567 currently recruiting?
Yes, NCT06703567 is actively recruiting participants. Contact the research team at gabriella.pravettoni@ieo.it for enrollment information.
Where is the NCT06703567 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT06703567 clinical trial?
NCT06703567 is sponsored by European Institute of Oncology. The principal investigator is Gabriella Pravettoni, MD at European Istitute of Oncology. The trial plans to enroll 82 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.